Angelica sinensis polysaccharide attenuates constipation-associated colorectal carcinogenesis by inhibiting the NLRP3/Caspase-1/IL-1β inflammasome axis
World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)
DOI: 10.4251/wjgo.121010 ↗Abstract
BACKGROUND Chronic constipation-associated inflammation is a global public health threat as end-stage colorectal malignancy continues to rise worldwide. Aberrant innate immune signaling, especially via NOD-like receptor protein 3 (NLRP3) inflammasome–caspase-1-interleukin-1 beta (IL-1β) cascade, has emerged as a molecular driver of chronic colonic epithelial inflammation in response to prolonged exposure to the secondary bile acids that accumulate during episodes of constipation. Angelica sinensis polysaccharide (ASP) is a major bioactive macromolecule isolated from the traditional medicinal plant Angelica sinensis (Oliv.) Diels (Danggui), which shows wide-spectrum anti-inflammatory and immunomodulatory bioactivity, but modulating this particularly signaling axis in constipation-related colorectal carcinogenesis has not been clarified. AIM To investigate whether ASP inhibits the NLRP3/caspase-1/IL-1β inflammasome signaling pathway to attenuate deoxycholic acid (DCA)-induced chronic colonic epithelial inflammation and early neoplastic transformation, thereby establishing a mechanistic basis for ASP as a chemopreventive candidate against constipation-associated colorectal cancer. METHODS NCM460 cells – a well-characterized normal human colon mucosal epithelial cell line, were exposed separately to vehicle control, or used as osmotic control and treated with vehicle plus equimolar sodium chloride, or 200 μM DCA and co-treated with ASP at 2 increasing concentrations (ASP-L and ASP-H). Nigericin, a classical NLRP3 activator that was used to reinvite inflammasome activity, and a series of selective pharmacological probes – the NLRP3-specific inhibitors MCC950 and cycplase 09, the potassium ionophore nigericin as well as the caspase-1 selective inhibitor VX-765 – were utilized for mechanistic dissection. Immunofluorescence was used to determine the localization and abundance of NLRP3, ASC, and cleaved caspase-1. Reverse-transcription PCR and ELISA were used to measure messenger RNA and secreted protein levels of IL-1β, IL-18, tumor necrosis factor-alpha, IL-6, COX-2 and matrix metalloproteinase-9. Markers of epithelial-mesenchymal transition and cellular proliferation were further examined to determine early neoplastic transformation. RESULTS DCA challenge remarkably induced the expression of NLRP3, ASC and cleaved caspase-1 as well as all six downstream inflammatory mediators at both transcript and protein levels in NCM460 cells, along with up-regulating epithelial-mesenchymal transition marker genes and promoting cell proliferation. The changes to these parameters were dose-dependently reversed by ASP; in the case of the third exposure (higher concentration), all parameters were close to baseline levels. The activation of caspase-1 and IL-1beta by Nigericin was restored in the presence of ASP, but co-treating with either MCC950 or VX-765 completely inhibited this rebound proven that NLRP3/caspase-1 pathwayspecifiselectivity. Cycplase 09 and VX-765 significantly suppressed all six inflammatory mediators in ASP + nigericin cultures, as confirmed by reverse-transcription PCR and ELISA analyses. CONCLUSION ASP inhibits the NLRP3/caspase-1/IL-1β pathway and protects DCA-induced inflammatory injury of colonic epithelial cells and early neoplastic transformation in vitro. These mechanistic insights warrant additional preclinical and clinical testing of ASP as a chemopreventive agents for constipation-related colorectal cancer risk.
EUVIMED